anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain the subject composition having a rapidly improved emulsion stability, useful as a cosmetic, etc., by making the composition include an inorganic salt and a specific pentanediol. SOLUTION: This composition comprises (A) an inorganic salt and (B) 1,2- pentanediol. The component A is preferably one or more selected from sodium chloride, magnesium chloride, sodium sulfate, potassium chloride, potassium bromide and calcium chloride. Especially bittern is preferably used. For example the amount of the component A is 0.01-10.0 wt.% and that of the component B is 0.1-20.0 wt.% based on the whole amount of the emulsion composition. The composition is preferably formulated with an emulsifying agent, a polyhydric alcohol such as glycerol, 1,3-butylene glycol, etc., a humectant such as an amino acid or a mucosaccharide and components such as a ultraviolet absorber, an antioxidant, etc.
Because buspirone can bind to central dopamine receptors, a question has been raised about its potential to cause acute and chronic changes in dopamine-mediated neurological function (eg. dystonia, pseudo-parkinsonism, akathisia, and tardive dyskinesia). Clinical experience in controlled trials has failed to identify any significant neuroleptic-like activity; however, a syndrome of restlessness, appearing shortly after initiation of treatment, has been reported in some small fraction of buspirone-treated patients. The syndrome may be explained in several ways. For example, buspirone may increase central noradrenergic activity; alternatively, the effect may be attributable to dopaminergic effects (i.e., represent akathisia). See ADVERSE REACTIONS: Postmarketing Experience.
Non-invasive measurements duration with HS-1000 device will be for at least 30 minutes and up to 1 hour of aggregate recording either continuously in the event the patient's clinical condition allows it or in separate recording iterations in the event patient's condition will not allow continuous recording. For each patient, there may be several monitoring intervals from three times a day and up to as long as the patient undergoes brain monitoring, per the discretion of the investigator, patient and/or family members.
BACKGROUND: Modulated by differences in genetic and environmental factors, laboratory mice often show progressive weight gain, eventually leading to obesity and metabolic dyshomeostasis. Since the geroneuroprotector CMS121 has a positive effect on energy metabolism in a mouse model of type 2 diabetes, we investigated the potential of CMS121 to counteract the metabolic changes observed during the ageing process of wild type mice.
METHODS: Control or CMS121-containing diets were supplied ad libitum for 6 months, and mice were sacrificed at the age of 7 months. Blood, adipose tissue, and liver were analyzed for glucose, lipids, and protein markers of energy metabolism.
RESULTS: The CMS121 diet induced a 40% decrease in body weight gain and improved both glucose and lipid indexes. Lower levels of hepatic caspase 1, caspase 3, and NOX4 were observed with CMS121 indicating a lower liver inflammatory status. Adipose tissue from CMS121-treated mice showed increased levels of the transcription factors Nrf1 and TFAM, as well as markers of mitochondrial electron transport complexes, levels of GLUT4 and a higher resting metabolic rate. Metabolomic analysis revealed elevated plasma concentrations of short chain acylcarnitines and butyrate metabolites in mice treated with CMS121.
CONCLUSIONS: The diminished de novo lipogenesis, which is associated with increased acetyl-CoA, acylcarnitine, and butyrate metabolite levels, could contribute to safeguarding not only the peripheral system but also the aging brain. By mimicking the effects of ketogenic diets, CMS121 holds promise for metabolic diseases such as obesity and diabetes, since these diets are hard to follow over the long term.
A method for reducing pre-authorization turnaround time is disclosed. The method includes, at a database, receiving historical data including a historical pre-authorization request and clinical information associated with a historical pre-authorization request. The method further includes receiving real-time data using an API gateway including real-time pre-authorization requests wherein the real-time data includes the real-time pre-authorization procedure and a clinical document category. The method further includes removing irrelevant data from real-time data and historical data to produce clean historical data and clean real-time data. The method further includes extracting data features required to train a machine learning model from the clean historical data and clean real-time data. The method further includes training the machine learning model by applying the extracted data features from the clean historical data and clean real-time data. The method further includes identifying prediction data results by applying the trained machine learning model.
It has been reported that during isometric upper and lower extremity flexion exercises in individuals with chronic nonspecific low back pain (CSNLP), the mobility of the diaphragm decreases, especially in the anterior-middle portions. The regulation of intra-abdominal pressure is impaired due to insufficient mobility of the diaphragm and causes compressive forces on the vertebrae due to the compensatory activity of the superficial spinal extensors. Muscle imbalance between the upper and lower quadrants also results in an abnormal position of the chest or rib cage, negatively affecting lung function and exercise capacity. When the positive effects of the recently popular "Dynamic Neuromuscular Stabilization (DNS)" approach are examined, it suggests that it may be a possible treatment option in geriatric individuals with CSNLP. Based on the principles of developmental kinesiology, the DNS approach takes advantage of infants' motor development curves in the treatment of motor disorders. The main focus is on regulating intra-abdominal pressure and the integrated spinal stabilizing system through specific functional exercises based on the positions exhibited by a healthy infant. According to the DNS, every developmental position is an exercise position, but every exercise must follow basic principles. These principles are restoration of correct respiratory pattern and intra-abdominal pressure, respectively; ensuring correct support during dynamic activities of the extremities and ensuring biomechanical alignment during movement. Considering the principles of exercise, there appears to be a potential mechanism of action for anomalies in geriatric individuals with CNSLBP. Therefore, in our study, we aimed to examine the effect of DNS approach on functional movement patterns, balance, quality of life and exercise capacity in geriatric individuals with CNSLBP. It is the first randomized controlled study in the literature, and our hypothesis is that the DNS approach may be an effective therapeutic approach on these parameters.
In Sweden as in most other countries, the rate of induction of labor (IOL) has steadily increased, peaking at 27% of all deliveries in 2020. Due to recently published studies showing decreased perinatal mortality with IOL at 41 instead of 42 gestational weeks, national guidelines have changed to offering all pregnant women reaching 41 weeks IOL, which will increase induction rates and subsequent cost of IOL for medication further.

Spontaneous onset of labor is usually preferred, as it generally means lower risk of complications compared to IOL. If delivery needs to be induced in women with an unfavorable cervical status, an oral solution of misoprostol is a safe and inexpensive method that is easy to control and provides a high success rate of vaginal deliveries with a very low risk of hyper stimulation. Since the preparation of misoprostol (Cytotec®) has been used off-label with the solution being prepared locally at every unit, the profession has been looking for alternatives. Angusta® 25 ug tablets is the alternative that has been developed and approved but without being compared to the oral solution of misoprostol, the most commonly used method for IOL in Sweden. In addition, Angusta® is 43 times more expensive (1011 SEK compared to 23.60 SEK for Cytotec® for eight doses) considering "a typical induction" for primiparous women. Both methods are currently in use in clinical practice in Sweden.

A recent study conducted in Sweden 2020 shows that the Area Under the Curve (AUC) for the concentration in the blood of misoprostol after administration of 25 ug Cytotec® po compared to Angusta® 25ug po differs . The AUC is 32.9% higher with Cytotec® compared to Angusta®. The lower AUC for Angusta® may result in lower efficacy and time to delivery. However, this is unknown. The reason for this difference may be that a greater proportion of misoprostol is absorbed buccally and/or sublingually with use of misoprostol as a solution compared to when it is used as a tablet. Misoprostol has significantly different effect on uterine contractility depending on method of administration(1). Thus, using Angusta® may result in negative health economic outcomes due to higher price and in addition, a longer time spent in the delivery unit. No comparison of these two formulations has been performed in clinical practice.
Experimental: binary rhythm The randomized group for binary-rhythm intervention will receive a 12-week intervention with dance lessons. Classes will be divided into: Heating and stretching (5 minutes), main part (binary) (35 minutes) and relaxation (5 minutes).
The present invention relates to the use of solutions for injection of atosiban and to a method for stabilization. In one aspect, the present invention relates to the use of a composition comprising atosiban or a pharmaceutically acceptable salt thereof for the preparation of an oxytocin competitive antagonist for pregnant women in need thereof for the delay of upcoming premature delivery. The composition comprises a therapeutically effective amount of atosiban or a pharmaceutically acceptable salt thereof, such as atosiban acetate. The composition is a solution preparation for injection; for example, the composition of the solution formulation contains 7.5mg of atosiban or a pharmaceutically acceptable salt thereof per 1ml of atosiban as atosiban Ban Ji. The invention also relates to a pharmaceutical composition comprising atosiban or a pharmaceutically acceptable salt thereof, such as acetate, and to a process for the preparation of the pharmaceutical composition. The pharmaceutical composition of the present invention may be used in pregnant women in need thereof to delay the forthcoming premature delivery.
A system for selecting a preferred intraocular lens for implantation into an eye includes a controller having a processor and a tangible, non-transitory memory. The controller is configured to obtain diagnostic data of the eye, and obtain historical data composed of historical sets of patient data. The controller is configured to analyze individual risk factors based on the diagnostic data and obtain a weighted combination of the individual risk factors. A respective satisfaction metric for the plurality of intraocular lenses is generated based on the historical data. A preferred intraocular lens may be selected based in part on the respective satisfaction metric and the weighted combination. A visual simulation for each of the plurality of intraocular lenses may be performed, based in part on the diagnostic data. The visual simulation may incorporate an impact of the tear film data.
The process for developing Adapted TranS-C has been iterative and grounded in theory, data and stakeholder feedback. The core elements of the evidence-based theory of change underpinning TranS-C have been retained. Adapted TranS-C is delivered in four 20-minute, weekly, individual sessions.
Accumulating evidence has highlighted the importance of immune cells in the pathogenesis of chronic obstructive pulmonary disease (COPD). However, the understanding of the causal association between immunity and COPD remains incomplete due to the existence of confounding variables. In this study, we employed a two-sample Mendelian randomization (MR) analysis, utilizing the genome-wide association study database, to investigate the causal association between 731 immune-cell signatures and the susceptibility to COPD from a host genetics perspective. To validate the consistency of our findings, we utilized MR analysis results of lung function data to assess directional concordance. Furthermore, we employed MR-Egger intercept tests, Cochrane's Q test, MR-PRESSO global test, and "leave-one-out" sensitivity analyses to evaluate the presence of horizontal pleiotropy, heterogeneity, and stability, respectively. Inverse variance weighting results showed that seven immune phenotypes were associated with the risk of COPD. Analyses of heterogeneity and pleiotropy analysis confirmed the reliability of MR results. These results highlight the interactions between the immune system and the lungs. Further investigations into their mechanisms are necessary and will contribute to inform targeted prevention strategies for COPD.
The invention provides a sweat-dispelling fresh liquid. The fresh liquid is mainly used to dispel sweat and stop sweat, and leaves fragrance. The fresh liquid can have ideal sweat decomposition, sterilization, anti-inflammation and refreshing effects on oxter perspiration. The fresh liquid employs pure natural plant extracts as main components with no addition of any toxic chemical substances. The fresh liquid has no skin irritation, and can contact skin directly. The fresh liquid can be used anytime. The fresh liquid is sprayed towards oxters, and can decompose and dispel sweat effectively. The ingredients of the fresh liquid comprise tannic acid, small green bamboo extract, mint, deionized water, alga extract, formaldehyde solution and calendula extract. The above ingredients are mixed and prepared into a convenient, rapid, practical and health-care product for external use for people. The fresh liquid is suitable for popularization and application.
BACKGROUND: Cancer stem cells (CSCs) are a small population of cells in tumor tissues that can drive tumor initiation and promote tumor progression. A small number of previous studies indirectly mentioned the role of F-box and WD repeat domain-containing 7 (FBXW7) as a tumor suppressor in Triple-negative breast cancer (TNBC). However, few studies have focused on the function of FBXW7 in cancer stemness in TNBC and the related mechanism.
METHODS: We detected FBXW7 by immunohistochemistry (IHC) in 80 TNBC patients. FBXW7 knockdown and overexpression in MD-MBA-231 and HCC1937 cell models were constructed. The effect of FBXW7 on malignant phenotype and stemness was assessed by colony assays, flow cytometry, transwell assays, western blot, and sphere formation assays. Immunoprecipitation-Mass Spectrometry (IP-MS) and ubiquitination experiments were used to find and verify potential downstream substrate proteins of FBXW7. Animal experiments were constructed to examine the effect of FBXW7 on tumorigenic potential and cancer stemness of TNBC cells in vivo.
RESULTS: The results showed that FBXW7 was expressed at low levels in TNBC tissues and positively correlated with prognosis of TNBC patients. In vitro, FBXW7 significantly inhibited colony formation, cell cycle progression, cell migration, EMT process, cancer stemness and promotes apoptosis. Further experiments confirmed that chromodomain-helicase-DNA-binding protein 4 (CHD4) is a novel downstream target of FBXW7 and is downregulated by FBXW7 via proteasomal degradation. Moreover, CHD4 could promote the nuclear translocation of β-catenin and reverse the inhibitory effect of FBXW7 on β-catenin, and ultimately activate the Wnt/β-catenin pathway. Rescue experiments confirmed that the FBXW7-CHD4-Wnt/β-catenin axis was involved in regulating the maintenance of CSC in TNBC cells. In animal experiments, FBXW7 reduced CSC marker expression and suppressed TNBC cell tumorigenesis in vivo.
CONCLUSIONS: Taken together, these results highlight that FBXW7 degrades CHD4 protein through ubiquitination, thereby blocking the activation of the Wnt/β-catenin pathway to inhibit the stemness of TNBC cells. Thus, targeting FBXW7 may be a promising strategy for therapeutic intervention against TNBC.
Francisella tularensis is the bacterial pathogen that causes tularemia in humans and a number of animals. To date, no approved vaccine exists for this widespread and life-threatening disease. The present disclosure provides attenuated Francisella mutants that include genetic inactivations in two genes. The Francisella mutants contain a genetic inactivation in at least one gene selected from dsbB, FTT0742, pdpB,fumA, and carB, and at least one gene selected from tolB, htrB, ipxH, ostAl, fimT, ipcC, manB, manC, nusA, wzx, kdtA, FTN0408, FTN0757 and FTN1254. Also provided are immunogenic compositions that include the attenuated bacteria. Methods are provided for treatment (e.g., treatment of tularemia) using the attenuated Francisella mutants.
A bioabsorbable tracheal stent is provided. The bioabsorbable stent comprises a biodegradable polymer, wherein the “ biodegradable polymer comprises about 0 to 30 wt % glycerol, polyethylene glycol, triethyl citrate, or mixture thereof. A drug is dispersed within or dissolved in the biodegradable polymer. In a second and third aspect, the invention relates to methods of manufacturing a bioabsorbable tracheal stent. The first method includes forming a solution comprising a biodegradable polymer and a drug, the biodegradable polymer comprising about 0 to 30 wt % glycerol, polyethylene glycol, triethyl citrate, or mixture thereof. The method further comprises casting the solution to form the bioabsorbable tracheal stent. The second method includes forming a polymeric stent, and dip casting the polymeric stent in a solution comprising a biodegradable polymer and a drug to form a coating on the polymeric stent, wherein the biodegradable polymer comprises about 0 to 30 wt % glycerol, polyethylene glycol, triethyl citrate, or mixture thereof.
Total knee arthroplasty (TKA) risks persistent pain and long-term opioid use (LTO). The role of social determinants of health (SDoH) in LTO is not well established. We hypothesized that SDoH would be associated with postsurgical LTO after controlling for relevant demographic and clinical variables. This study utilized data from the Veterans Affairs Surgical Quality Improvement Program, VA Corporate Data Warehouse, and Centers for Medicare and Medicaid Services, including Veterans aged ≥ 65 who underwent elective TKA between 2013 and 2019 with no postsurgical complications or history of significant opioid use. LTO was defined as > 90 days of opioid use beginning within 90 days postsurgery. SDoH variables included the Area Deprivation Index, rurality, and housing instability in the last 12 months identified via medical record screener or International Classification of Diseases, Tenth Revision codes. Multivariable risk adjustment models controlled for demographic and clinical characteristics. Of the 9,064 Veterans, 97% were male, 84.2% white, mean age was 70.6 years, 46.3% rural, 11.2% living in highly deprived areas, and 0.9% with a history of homelessness/housing instability. Only 3.7% (n = 336) developed LTO following TKA. In a logistic regression model of only SDoH variables, housing instability (odds ratio [OR] = 2.38, 95% confidence interval [CI]: 1.09-5.22) and rurality conferred significant risk for LTO. After adjusting for demographic and clinical variables, LTO was only associated with increasing days of opioid supply in the year prior to surgery (OR = 1.52, 95% CI: 1.43-1.63 per 30 days) and the initial opioid fill (OR = 1.07; 95% CI: 1.06-1.08 per day). Our primary hypothesis was not supported; however, our findings do suggest that patients with housing instability may present unique challenges for postoperative pain management and be at higher risk for LTO.
At 00:00 the night before the surgery, the researcher told the patients in the control group that they could have fruit juice/water if they wanted and waited for 10 minutes. The researcher then initiated the restriction process by informing the patients that they could no longer have food/water. Fasting, thirst, blood glucose and nausea-vomiting evaluations applied to the patients in the intervention group were also performed on the patients in the control group at the same hours. IV fluid therapy was not administered to both groups before surgical intervention.
1385131 Detergents containing polymeric builders ICI AMERICA Inc 12 Jan 1973 [18 Feb 1972] 1770/73 Heading C5D A detergent composition for cleansing and laundering operations comprises an organic water-soluble detergent surfactant and, as polymeric builder, a water-soluble salt of a maleic acid-vinyl alcohol copolymer, derived from a prepolymer in which vinyl acetate is the precursor for the vinyl alcohol moiety. The salt of the copolymer may be an alkali metal, ammonium or substituted ammonium salt. The copolymer has a molecular weight of 500 to 50,000 and a ratio of maleic acid to vinyl alcohol of 2 : 3 to 3 : 2. The copolymers are prepared by the hydrolysis of a maleic anhydridevinyl acetate copolymer by means of an alkali metal hydroxide or NH 4 OH and the builder also contains an acetate, e.g. sodium acetate produced by the hydrolysis step. The surfactant may be anionic, non-ionic, zwitterionic, ampholytic and mixtures thereof. Detergent compositions in liquid or powder form contains (A) 3-35% by wt. of detergent surfactant (B) 5-60% wt. of copolymer builder (C) 0-2% carboxymethyl cellulose (D) 5-20% alkali metal silicate (E) 0-60% alkali metal sulphate (F) 0-10% bleaching agent.